Drugs for postmenopausal osteoporosis.

Med Lett Drugs Ther

Published: July 2024

Download full-text PDF

Source
http://dx.doi.org/10.58347/tml.2024.1706aDOI Listing

Publication Analysis

Top Keywords

drugs postmenopausal
4
postmenopausal osteoporosis
4
drugs
1
osteoporosis
1

Similar Publications

The neuropathic characteristics of pain occurring after an osteoporosis (OP)-related fracture are often under-recognized. The aim of this pilot study is to identify, in patients suffering from pain localized on the site of a previous osteoporotic fracture, the presence of neuropathic characteristics, their medical management, and their impact on quality of life. This pilot cross-sectional study on consecutive patients in University Hospital, Rheumatology Department, Clermont-Ferrand, France, was approved by the Ethics Committee (IRB number 2023-CF34).

View Article and Find Full Text PDF

Background: Evidence has revealed that oestrogen deprivation-induced osteolysis is microbiota-dependent and can be treated by probiotics. However, the underlying mechanism require further investigation. This study aims to provide additional evidence supporting the use of probiotics as an adjuvant treatment and to explore the pathophysiology of oestrogen-deprived osteolysis.

View Article and Find Full Text PDF

Background: The physical and mental changes created during menopause cause sexual dysfunction, which affects the quality of life, self-esteem, and emotional relationships. Wormwood cream contains tannins, terpenoids, flavonoids, phytosterols, and alkaloids. The purpose of this study is to evaluate the safety and effectiveness of wormwood vaginal cream on the sexual satisfaction and quality of sexual life of postmenopausal women.

View Article and Find Full Text PDF

Background: Zhuanggu Shubi ointment (ZGSBG) has good efficacy in postmenopausal osteoporosis (PMO), but the mechanism of efficacy involving gut microecology has not been elucidated.

Objective: This study investigated the mechanism of ZGSBG in regulating gut microecology in PMO.

Methods: The bilateral ovarian denervation method was used to construct a rat model of PMO and was administered ZGSBG.

View Article and Find Full Text PDF

Estrogen (E2) deficiency is a risk factor for cardiovascular disease (CVD), however, the exact mechanism for the E2 protective effect on CVD remains unclear. This study aimed to investigate the estrogen receptor (ER) and non-receptor mediated effects of E2 treatment on the cardiac expression of adenosine monophosphate-dependent protein kinase (AMPK), autophagic, mitophagy and mitochondrial homeostasis-regulating genes in ovariectomized (OVX) rats. Female rats were divided into two main groups; sham and bilaterally OVX rats, then each group was subdivided into four subgroups according to treatment; untreated, subcutaneously treated with E2 (30 μg/kg), or Fulvestrant (F) (5 mg/Kg), or a combination of both drugs for 28 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!